Mustang Bio to Present at the Phacilitate Leaders World & World Stem Cell Summit 2020
January 22, 2020 08:30 ET
|
Mustang Bio, Inc.
NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
December 09, 2019 07:30 ET
|
Mustang Bio, Inc.
MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID Enhanced transduction...
Mustang Bio to Participate in the Evercore ISI 2nd Annual HealthCONx Conference
December 02, 2019 08:30 ET
|
Mustang Bio, Inc.
NEW YORK, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
November 12, 2019 07:30 ET
|
Mustang Bio, Inc.
NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting
November 06, 2019 09:15 ET
|
Mustang Bio, Inc.
St. Jude Children’s Research Hospital and the National Institutes of Health to present updated MB-107 clinical data for the treatment of X-linked severe combined immunodeficiency Fred Hutchinson...
Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma
October 24, 2019 08:30 ET
|
Mustang Bio, Inc.
NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma
October 10, 2019 08:00 ET
|
Mustang Bio, Inc.
NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
Mustang Bio to Participate in October 2019 Investor Conferences
September 26, 2019 08:30 ET
|
Mustang Bio, Inc.
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
September 23, 2019 08:30 ET
|
Mustang Bio, Inc.
NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...
Mustang Bio to Present at Scientific Conferences in September 2019
September 09, 2019 08:00 ET
|
Mustang Bio, Inc.
NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and...